Auguet T et al (2014) Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. BioMed Res Int. https://doi.org/10.1155/2014/502542

Article  PubMed  PubMed Central  Google Scholar 

Avraham Y et al (2005) Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Res Bull 65(2):117–123

Article  CAS  PubMed  Google Scholar 

Bátkai S et al (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J: Off Publ Fed Am Soc Exp Biol 21(8):1788

Article  Google Scholar 

Behl T et al (2021) Understanding the possible role of endocannabinoid system in obesity. Prostaglandins Other Lipid mediat 152:106520

Article  CAS  PubMed  Google Scholar 

Bermudez-Silva FJ et al (2007) Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 565(1–3):207–211

Article  CAS  PubMed  Google Scholar 

Cotter DG et al (2014) Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Investig 124(12):5175–5190

Article  PubMed  PubMed Central  Google Scholar 

Dai E et al (2017) Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B. Int J Infect Dis 59:124–130

Article  CAS  PubMed  Google Scholar 

Denaës T et al (2016) The cannabinoid receptor 2 protects against alcoholic liver disease via a macrophage autophagy-dependent pathway. Sci Rep 6(1):28806

Article  PubMed  PubMed Central  Google Scholar 

Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Nhieu J-V et al (2009a) Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 4(6):e5844

Article  PubMed  PubMed Central  Google Scholar 

Flores-Contreras L et al (2014) Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol 14:1–11

Article  CAS  Google Scholar 

Fraga-Silva RA et al (2013) Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. J Immunol Res 2013(1):263846

Google Scholar 

Grohmann M et al (2018) Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 175(5):1289–1306

Article  CAS  PubMed  PubMed Central  Google Scholar 

Julien B et al (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128(3):742–755. https://doi.org/10.1053/j.gastro.2004.12.050

Article  CAS  PubMed  Google Scholar 

Kalkan H, Flamand N (2025) The CB₂ receptor in immune regulation and disease: genetic architecture, epigenetic control, and emerging therapeutic strategies

Kruk-Slomka M et al (2017) Endocannabinoid system: the direct and indirect involvement in the memory and learning processes—a short review. Mol Neurobiol 54(10):8332–8347. https://doi.org/10.1007/s12035-016-0313-5

Article  CAS  PubMed  Google Scholar 

Kubota N et al (1999) PPARγ mediates high-fat diet–induced adipocyte hypertrophy and insulin resistance. Mol Cell 4(4):597–609

Article  CAS  PubMed  Google Scholar 

Liu C-Y et al (2021) Ampk/Sirt1 pathway is involved in arctigenin-mediated protective effects against myocardial ischemia-reperfusion injury. Front Pharmacol 11:2351

Article  Google Scholar 

Long C et al (2021) Knockout of the cannabinoid receptor 2 gene promotes inflammation and hepatic stellate cell activation by promoting A20/nuclear factor-κB (NF-κB) expression in mice with carbon tetrachloride-induced liver fibrosis. Med Sci Monit 27:e931236-1

Article  Google Scholar 

Lotersztajn S et al (2008) CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153(2):286–289

Article  CAS  PubMed  Google Scholar 

Louvet A et al (2011) Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54(4):1217–1226

Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20(SUPPL. 1):10–14. https://doi.org/10.1111/j.1365-2826.2008.01671.x

Article  CAS  PubMed  Google Scholar 

Mahmoud MF et al (2014) Role of cannabinoid receptors in hepatic fibrosis and apoptosis associated with bile duct ligation in rats. Eur J Pharmacol 742:118–124. https://doi.org/10.1016/j.ejphar.2014.08.021

Article  CAS  PubMed  Google Scholar 

Mahmoud HM et al (2019) AM-1241 CB2 receptor agonist attenuates inflammation, apoptosis and stimulate progenitor cells in bile duct ligated rats. Open Access Macedonian J Med Sci 7(6):925

Article  Google Scholar 

Matheson J et al (2021) Potential of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), and diacylglycerol lipase (DAGL) enzymes as targets for obesity treatment: a narrative review. Pharmaceuticals 14(12):1316

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meex RCR, Blaak EE, van Loon LJC (2019) Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev 20(9):1205–1217

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mendez-Sanchez N et al (2007) Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 27(2):215–219. https://doi.org/10.1111/j.1478-3231.2006.01401.x

Article  CAS  PubMed  Google Scholar 

Montecucco F et al (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294(3):H1145–H1155

Article  CAS  PubMed  Google Scholar 

Muñoz-Luque J et al (2008) Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324(2):475–483

Article  PubMed  Google Scholar 

Nascimento AR et al (2013) Structural and functional microvascular alterations in a rat model of metabolic syndrome induced by a high-fat diet. Obesity 21(10):2046–2054

Article  CAS  PubMed  Google Scholar 

O’Keefe L et al (2023) Treatment of diet-induced obese rats with CB2 agonist AM1241 or CB2 antagonist AM630 reduces leptin and alters thermogenic mRNA in adipose tissue. Int J Mol Sci. https://doi.org/10.3390/ijms24087601

Article  PubMed  PubMed Central  Google Scholar 

Osei-Hyiaman D et al (2005) Endocannabinoid activation at hepatic CB 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Investig 115(5):1298–1305

Article  CAS  PubMed  PubMed Central  Google Scholar 

Páldyová E et al (2008) Noladin ether, a putative endocannabinoid, inhibits µ-opioid receptor activation via CB2 cannabinoid receptors. Neurochem Int 52(1):321–328. https://doi.org/10.1016/j.neuint.2007.06.033

Article  CAS  PubMed  Google Scholar 

Ratano P et al (2018) Pharmacological inhibition of 2-arachidonoilglycerol hydrolysis enhances memory consolidation in rats through CB2 receptor activation and mTOR signaling modulation, Neuropharmacology. Elsevier Ltd. Available at: https://doi.org/10.1016/j.neuropharm.2018.05.030

Rossi F et al (2012) ‘Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease’

Suk K-T et al (2016) Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut 65(10):1721–1732

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teixeira-Clerc F et al (2010) Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52(3):1046–1059. https://doi.org/10.1002/hep.23779